{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:39:01Z","timestamp":1779219541309,"version":"3.51.4"},"reference-count":114,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T00:00:00Z","timestamp":1359072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In clinical practice, latent infection with <jats:italic><jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>ycobacterium tuberculosis<\/jats:italic> is defined by the presence of an <jats:italic><jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>.\u2009tuberculosis<\/jats:italic>\u2010specific immune response in the absence of active tuberculosis. Targeted testing of individuals from risk groups with the tuberculin skin test or an interferon\u2010\u03b3 release assay is currently the best method to identify those with the highest risk for progression to tuberculosis. Positive predictive values of the immunodiagnostic tests are substantially influenced by the type of test, the age of the person who is tested, the prevalence of tuberculosis in the society and the risk group to which the person belongs. As a general rule, testing should only be offered when preventive chemotherapy will be accepted in the case of a positive test result. Preventive chemotherapy can effectively protect individuals at risk from the development of tuberculosis, although at least 3 months of combination therapy or up to 9 months of monotherapy are required, and overall acceptance rate is low. Improvements of the current generation of immunodiagnostic tests could substantially lower the number of individuals that need to be treated to prevent a case of tuberculosis. If shorter treatment regimens were equally effective than those currently recommended, acceptance of preventive chemotherapy could be much improved.<\/jats:p>","DOI":"10.1111\/resp.12002","type":"journal-article","created":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T15:30:10Z","timestamp":1351524610000},"page":"205-216","source":"Crossref","is-referenced-by-count":33,"title":["Diagnosis and treatment of latent infection with <i><scp>M<\/scp>ycobacterium tuberculosis<\/i>"],"prefix":"10.1111","volume":"18","author":[{"given":"CYNTHIA BIN\u2010ENG","family":"CHEE","sequence":"first","affiliation":[{"name":"TB Control Unit Department of Respiratory and Critical Care Medicine Tan Tock Seng Hospital  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARTINA","family":"SESTER","sequence":"additional","affiliation":[{"name":"Department of Transplant and Infection Immunology Saarland University  Homburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WENHONG","family":"ZHANG","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Fudan University  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHRISTOPH","family":"LANGE","sequence":"additional","affiliation":[{"name":"Clinical Infectious Diseases Tuberculosis Center Research Center Borstel  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,25]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"World Health Organization.Tuberculosis. Fact sheet \u00b0104.2012. [Accessed 9 Sep 2012.] Available from URL:http:\/\/www.who.int\/mediacentre\/factsheets\/fs104\/en\/"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a121593"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70210-9"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00120908"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00201609"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2009.02.005"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2236"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2236-c1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-009-0042-9"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro749"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00624-07"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.11.7474"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39143"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00028510"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2010.09.003"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068819"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283117f18"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/507427"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00214611"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1463OC"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2010.05.003"},{"key":"e_1_2_8_24_1","article-title":"Tuberculosis in the immunocompromised host","author":"Sester M","year":"2012","journal-title":"Eur. Resp. Monograph"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02742-2"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00013409"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00115110"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-3-200808050-00241"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05115-1"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201201-0026OC"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00114810"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03625.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0974OC"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200956"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00098509"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200912-1875OC"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0004"},{"key":"e_1_2_8_38_1","first-page":"1271","article-title":"Usefulness of enzyme\u2010linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti\u2010tumor necrosis factor treatment","volume":"35","author":"Vassilopoulos D","year":"2008","journal-title":"J. Rheumatol."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-008-0519-1"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09331.x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn748"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-56"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200608-1088OC"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1086\/597351"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00079310"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000712"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-012-0293-1"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"e_1_2_8_49_1","volume-title":"International Standards for Tuberculosis Care (ISTC)","author":"Tuberculosis Coalition for Technical Assistance","year":"2009"},{"key":"e_1_2_8_50_1","unstructured":"World Health Organization.WHO Policy on Collaborative TB\/HIV Activities: Guidelines for National Programmes and Other Stakeholders.World Health Organization Geneva 2012."},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2010.01751.x"},{"key":"e_1_2_8_52_1","first-page":"821","article-title":"The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis","volume":"85","author":"Mount FW","year":"1962","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_8_53_1","first-page":"490","article-title":"Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts","volume":"85","author":"Ferebee SH","year":"1962","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_8_54_1","first-page":"161","article-title":"A controlled trial of isoniazid prophylaxis in mental institutions","volume":"88","author":"Ferebee SH","year":"1963","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_8_55_1","first-page":"935","article-title":"A controlled trial of community\u2010wide isoniazid prophylaxis in Alaska","volume":"95","author":"Comstock GW","year":"1967","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_8_56_1","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow\u2010up in the IUAT trial","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","journal-title":"Bull. World Health Organ."},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03370120057023"},{"key":"e_1_2_8_58_1","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock GW","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_8_59_1","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"American Thoracic Society","year":"2000","journal-title":"MMWR Recomm. Rep."},{"issue":"1","key":"e_1_2_8_60_1","article-title":"Isoniazid for preventing tuberculosis in non\u2010HIV infected persons","author":"Smieja MJ","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1972.106.3.357"},{"key":"e_1_2_8_62_1","first-page":"991","article-title":"Isoniazid\u2010related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff DE","year":"1978","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.2.465"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1014"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200303-390OC"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.1.36"},{"key":"e_1_2_8_67_1","unstructured":"National Institute for Health and Clinical Excellence.Tuberculosis: clinical diagnosis and management of tuberculosis and measures for its prevention and control.2011. [Accessed 15 Nov 2012.] Available from URL:http:\/\/guidance.nice.org.uk\/CG117\/NICEGuidance\/pdf\/English"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1086\/647944"},{"key":"e_1_2_8_69_1","unstructured":"MenziesD.A randomized clinical trial comparing 4RIF vs 9INH for treatment of latent tuberculosis infection (LTBI)\u2014effectiveness.2012. [Accessed 10 Sep 2012.] Available from URL:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00931736"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1086\/427802"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.5.2003028"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1086\/520983"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709183371201"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199818000-00014"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06532-X"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.11.1445"},{"key":"e_1_2_8_77_1","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003","volume":"52","author":"American Thoracic Society\/Centers of Disease Control and Prevention","year":"2003","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200512-1953OC"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005136"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"e_1_2_8_81_1","first-page":"1650","article-title":"Recommendations for use of an isoniazid\u2010rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","author":"Centers of Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199903110-00009"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000171.pub3"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200111090-00009"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101260-00011"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60204-3"},{"key":"e_1_2_8_87_1","unstructured":"World Health Organization.Guidelines for Intensified Tuberculosis Case\u2010Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource\u2010Constrained Settings.World Health Organization Geneva 2011."},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.5.8912767"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.155.5.9154885"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0437"},{"key":"e_1_2_8_91_1","first-page":"61","article-title":"Management of persons exposed to multidrug\u2010resistant tuberculosis","volume":"41","author":"Centers of Disease Control and Prevention","year":"1992","journal-title":"MMWR Recomm. Rep."},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.9.701.34065"},{"key":"e_1_2_8_93_1","first-page":"131","article-title":"Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug\u2010resistant tuberculosis","volume":"167","author":"Papastavros T","year":"2002","journal-title":"CMAJ"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00006205"},{"key":"e_1_2_8_95_1","volume-title":"Drug\u2010Resistant Tuberculosis: A Survival Guide for Clinicians","author":"Curry International Tuberculosis Center and California Department of Public Health","year":"2008"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70366-8"},{"key":"e_1_2_8_97_1","first-page":"12","article-title":"Chapter 4: childhood contact screening and management","volume":"11","author":"Stop TB Partnership Childhood TB subgroup","year":"2007","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_8_98_1","volume-title":"Management of Contacts of MDR TB and XDR TB Patients","author":"European Centre for Disease Prevention and Control","year":"2012"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017813"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2299"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242950"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.8.5217"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011670"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015619"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2011.01.001"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1586\/ers.09.31"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1586\/erm.11.97"},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09247"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024290"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0246"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e32833159f2"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.6.2004022"},{"key":"e_1_2_8_113_1","first-page":"780","article-title":"How much isoniazid is needed for prophylaxis?","volume":"101","author":"Comstock GW","year":"1970","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1613OC"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201011-1881ED"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fresp.12002","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.12002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T17:50:01Z","timestamp":1697305801000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.12002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,25]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/resp.12002"],"URL":"https:\/\/doi.org\/10.1111\/resp.12002","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,25]]}}}